NSCLC Adjuvant Targeted Therapy
Sort by:
Dana-Farber Cancer Institute
Risk of Hepatotoxicity From Sequential IO Followed by KRASG12C Targeted Therapy in NSCLC
FEATURING
Biagio Ricciuti
- 231 views
- May 22, 2024
- 2
UChicago Medicine 12th International Clinical Cancer Genomics Conference
Precision Medicine in NSCLC
FEATURING
Stacy Gray
- 290 views
- May 15, 2024
- 3
Santiago Viteri
The VISION Trial: Tepotinib in Patients With NSCLC Harboring METex14 Skipping Mutation
- 143 views
- May 10, 2024
- 1
UCLA Health
HERTHENA-Lung01 Study: Patritumab Deruxtecan as a HER3 Target in EGFRm Advanced NSCLC
FEATURING
Aaron Lisberg
- 166 views
- May 9, 2024
- 1
Insights from ELCC 2024
ELCC 2024 Insights: "AI for Diagnosis and Predictive Biomarkers in Thoracic Oncology"
FEATURING
Paul Hofman
- 127 views
- May 9, 2024
- 2
Icahn School of Medicine at Mount Sinai
PanRAF Inhibitors in NSCLC
FEATURING
Rajwanth Veluswamy
- 42 views
- May 7, 2024
Yale Cancer Center
Investigating the Complex Biology of Drug Resistance for Clinical Impact in Lung Cancer
FEATURING
Katerina Politi
- 28 views
- May 2, 2024
GRACE
Antibody Drug Conjugates and How They Are Used in NSCLC
FEATURING
Lyudmila Bazhenova
- 34 views
- May 1, 2024
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
Changing Systemic Therapy Post Oligoprogression in the CNS
FEATURING
Gregory Riely
- 286 views
- April 30, 2024
- 3
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis
The Changing Prognosis of Lung Cancer Brain Metastases
FEATURING
Sarah Goldberg
- 351 views
- April 30, 2024
- 4
Insights from ELCC 2024
Advancing Lung Adenocarcinoma Treatment: Establishing KRAS-Driven Organoids for Drug Screening
FEATURING
Isa Tas
- 120 views
- April 18, 2024
Insights from ELCC 2024
ELCC 2024 Summary: "Combining New Drugs and RT in Lung Cancer"
FEATURING
Deborah Zhou
- 170 views
- April 10, 2024
Insights from TTLC 2024 Annual Meeting
TTLC 2024 Insights: "NTRK and NRG Fusions in NSCLC"
FEATURING
Liza Villaruz
- 317 views
- March 5, 2024
Yale Cancer Center
Targeting Drug-Tolerant Persister Cells: Osimertinib Combinations in NSCLC
FEATURING
Pasi Janne
- 196 views
- February 23, 2024
- 1
Yale Cancer Center
2024 Updates on NSCLC Targeted Therapies: New Drug Targets in EGFRm Disease - TROP2
FEATURING
Pasi Janne
- 120 views
- February 23, 2024
- 2
OncoAlert
Updates in Targeted Therapies for Solid Tumors
FEATURING
Benedikt Westphalen
- 66 views
- February 17, 2024
OncoAlert
mNSCLC Updates: 1L EGFRm, 2/3L EGFRm & Anti-Trop2 ADC
FEATURING
Charu Aggarwal
- 388 views
- February 15, 2024
- 2